Relations between professional medical associations and the health-care industry, concerning scientific communication and continuing medical education: A Policy Statement from the European Society of Cardiology
Board E.S.C.,Sophia Office
European Heart Journal | Year: 2012
Physicians have an ethical duty to keep up-to-date with current knowledge. Professional medical associations such as the European Society of Cardiology (ESC) support these obligations. In Europe, the costs of continuing medical education (CME) are insufficiently supported from governments and employers; however, medical associations have been criticized for accepting alternative financial support from industry. Medical education and training in research include learning how to assess the quality and reliability of any information. There is some risk of bias in any form of scientific communication including intellectual, professional, and financial and it is essential that in particular, the latter must be acknowledged by full disclosure. It is essential that there is strong collaboration between basic and clinical researchers from academic institutions on the one hand, with engineers and scientists from the research divisions of device and pharmaceutical companies on the other. This is vital so that new diagnostic methods and treatments are developed. Promotion of advances by industry may accelerate their implementation into clinical practice. Universities now frequently exhort their academic staff to protect their intellectual property or commercialize their research. Thus, it is not commercial activity or links per se that have become the target for criticism but the perceived influence of commercial enterprises on clinical decision-making or on messages conveyed by professional medical organizations. This document offers the perspective of the ESC on the current debate, and it recommends how to minimize bias in scientific communications and CME and how to ensure proper ethical standards and transparency in relations between the medical profession and industry. © 2011 The Author.
Brachet C.,Sophia Office |
Levite H.,Water Resources Coordination Center |
Tengnas A.,Water Resources Coordination Center |
Ouedraogo I.,Water Resources Coordination Center
International Journal on Hydropower and Dams | Year: 2013
The potential for hydropower production in West Africa has been estimated at around 24 000 MW, but only 10 per cent has been developed so far. The rate of irrigation development is about the same (12 per cent). Although the region has enormous renewable water resources, these are under-utilized mainly for economic reasons, a fact defined by IWMI as economic water scarcity. Many large dam projects are currently in the pipeline in West Africa. However, some of them have been waiting for a very long time, in some cases more than 50 years. To clarify the status of these projects, ECOWAS water unit launched in 2009 the "Dialogue on large water infrastructures in West Africa", an initiative aimed at revitalizing a number of existing projects.
Hoefnagel D.,Sophia Office |
Kwee L.E.,Sophia Office |
Van Putten E.H.P.,Slotervaartziekenhuis |
Kros J.M.,Erasmus University Rotterdam |
And 2 more authors.
Clinical Neurology and Neurosurgery | Year: 2014
Background Patients with meningiomas carry an increased risk for postoperative venous thromboembolic complications (VTE) including deep venous thrombosis (DVT) and pulmonary embolism (PE). Objective In the present retrospective study we investigated the incidence of VTE and the risk factors involved, in a large cohort of patients surgically treated for an intracranial meningioma at our institution. Methods During the period from January 1997 to January 2009, 581 consecutive patients underwent craniotomy for intracranial meningioma. All patients received low-molecular weight heparins as thromboembolism prophylaxis. Patient demographics and tumor characteristics were gathered via retrospective chart review. Postoperative VTE and hemorrhages were noted. Backward stepwise logistic regression was used to determine the risk factors. Results 80.6% of meningiomas were WHO grade 1; 15.1% WHO grade 2; 4.3% WHO grade 3. Postoperative VTE were observed in 41 patients (7.2%). Of these, DVT was seen in 20 (3.5%) and PE in 26 patients (4.6%). The thromboembolic complication appeared on average 21.1 ± 29.2 days post surgery. The 90-day mortality rate after VTE was 11.2% (23.1% for PE and 5.0% for DVT). Postoperative hemorrhages requiring surgical treatment were found in 2.9% of patients. Risk factors for VTE were body mass index (p = 0.015) for DVT; weight (p = 0.001) and bedridden postoperatively (p = 0.001) for PE; and weight (p = 0.004) and bedridden postoperatively (p = 0.003) for VTE in general. There was no relation between tumor grade and thromboembolic complications. Conclusion The major risk factors for postoperative VTE found in our single center study are patient weight and a bedridden status postoperatively. Prophylactic intervention for this potentially fatal complication should be evaluated against the relative lower risk of postoperative hemorrhages. © 2014 Elsevier B.V.
Otten M.H.,Sophia Office |
Prince F.H.M.,Sophia Office |
Ten Cate R.,Leiden University |
Van Rossum M.A.J.,Jan Medical |
And 11 more authors.
Annals of the Rheumatic Diseases | Year: 2011
Objectives: To evaluate the effectiveness of tumour necrosis factor (TNF) blockers in juvenile psoriatic arthritis (JPsA). Methods: The study was a prospective ongoing multicentre, observational study of all Dutch juvenile idiopathic arthritis (JIA) patients using biologicals. The response of arthritis was assessed by American College of Rheumatology (ACR) paediatric response and Wallace inactive disease criteria. The response of psoriatic skin lesions was scored by a 5-point scale. Results: Eighteen JPsA patients (72% female, median age onset 11.1 (range 3.3-14.6) years, 50% psoriatic skin lesions, 39% nail pitting, 22% dactylitis) were studied. The median follow-up time since starting anti-TNFα was 26 (range 3-62) months. Seventeen patients started on etanercept and one started on adalimumab. After 3 months of treatment 83% of the patients achieved ACR30 response, increasing to 100% after 15 months. Inactive disease reached in 67% after 39 months. There was no discontinuation because of inefficacy. Six patients discontinued treatment after a good clinical response. However, five patients flared and restarted treatment, all with a good response. During treatment four patients (two JPsA and two JIA patients with other subtypes) developed de novo psoriasis. In four of the nine patients the pre-existing psoriatic skin lesions improved. Conclusion: Anti-TNFα therapy in JPsA seems effective in treating arthritis. However, in most patients the arthritis flared up after treatment discontinuation, emphasising the need to investigate optimal therapy duration. The psoriatic skin lesions did not respond well and four patients developed de novo psoriasis.